• Version
• Download 86657
• File Size 0.00 KB
• File Count 1
• Create Date March 9, 2025
• Last Updated March 9, 2025

A Diabetic Male with Arteriosclerosis and Pericardial Cyst Treated by Imeglimin

Hiroshi Bando^1,2,3iD*, Tomoya Ogawa³, Kazuki Sakamoto³, Maki Okada³, Noboru Iwatsuki^3
1Medical Research/Tokushima University, Tokushima, Japan
²Japan Low Carbohydrate Diet Promotion Association, Kyoto, Japan
³Sakamoto Hospital, Higashi Kagawa city, Kagawa, Japan

Corresponding Author: Hiroshi Bando ^{ORCID iD}
Address: Tokushima University /Medical Research, Nakashowa 1-61, Tokushima 770-0943, Japan.
Received date: 01 January 2025; Accepted date: 29 January 2025; Published date: 06 February 2025

Citation: Bando H, Ogawa T, Sakamoto K, Okada M, Iwatsuki N. A Diabetic Male with Arteriosclerosis and Pericardial Cyst Treated by Imeglimin. Asp Cardio Case Rep and Res. 2025 Feb 06;2(1):11-16.

Copyright © 2025 Bando H, Ogawa T, Sakamoto K, Okada M, Iwatsuki N. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.

Keywords: Pulse Wave Velocity, Atherosclerotic Cardiovascular Disease, Standard of Care-2025, American Diabetes Association, Imeglimin

Abbreviations: PWV: Pulse Wave Velocity; ASCVD: Atherosclerotic Cardiovascular Disease; SoC-2025: Standard of Care-2025; ADA: American Diabetes Association

Abstract

The patient is a 70-year-old male who developed back pain in May 2021. He was diagnosed with a ureteral stone and type 2 diabetes (T2D) with an HbA1c of 9.3% in 2021. After a successful operation, he continued treatment for T2D. Pulse wave velocity (PWV) showed an ankle-brachial index (ABI) of 0.78/0.83 (R/L) and a cardio-ankle vascular index (CAVI) of 12.9/13.9, suggesting arteriosclerosis and peripheral artery disease (PAD). Computed tomography (CT) showed a movable lesion adjacent to the right heart, suggesting a pericardial cyst. HbA1c had been stable after that but increased during the summer of 2024; he then started imeglimin (Twymeeg), which was associated with clinical efficacy and without gastrointestinal adverse effects (GI-AE).